1,721,582 research outputs found
DYSLIPOPROTEINEMIA IN MANIFEST DIABETES
No full textThe prevalence of hypercholesterolaemia is similar in non-insulin-dependent diabetic (NIDDM) patients and in non-diabetic subjects. The prevalence of hypertriglyceridaemia and of low high-density-lipoprotein (HDL) cholesterol is roughly double the norm in NIDDM, but the exact prevalence varies greatly from study to study. Obesity and a familial form of hypertriglyceridaemia (conditions that may alter plasma lipoprotein levels) are frequently observed in NIDDM patients. In carefully controlled NIDDM patients without concomitant primary hyperlipoproteinaemia, body weight may be more important than glycaemic control or the type of treatment plan adopted in determining lipoprotein levels. Hypertriglyceridaemia in NIDDM is a result of both increased very-low-density-lipoprotein (VLDL) synthesis and impaired VLDL catabolism. Whilst low-density-lipoprotein (LDL) levels are normal, the LDL synthesis and removal rates may be increased. Low high-density-lipoprotein (HDL) levels may be due to increased catabolism. In addition to quantitative changes in plasma lipids and lipoproteins. NIDDM patients demonstrate qualitative lipoprotein alterations. The size and density of LDL particles in NIDDM patients are greatly affected by triglyceride levels. Smaller, denser LDL particles have been observed in hypertriglyceridaemic subjects. Glycosylation of apolipoproteins may alter the metabolic properties of lipoproteins. Glycosylated and small, dense LDL have an increased susceptibility to oxidatio
MODIFICATION OF CARDIOVASCULAR RISK-FACTORS DURING ANTIHYPERTENSIVE TREATMENT - A MULTICENTER TRIAL WITH QUINAPRIL
No full textA large multicentre study involving 6003 [3044 males, 2959 females; mean (+/- SD) age 59 +/- 11 years] mild-to-severe hypertensive patients was carried out to evaluate the effects of the angiotension converting enzyme inhibitor quinapril on blood pressure and on metabolic cardiovascular risk factors during 3 - 6 months' treatment (mean follow-up 90.4 days). The study population included 551 elderly [mean (+/- SD) age 71.9 +/- 9.3 years] patients, 1314 subjects with diabetes mellitus and 154 non-diabetic patients with hyperlipaemia; 4% of patients were lost to follow-up. Diastolic blood pressure decreased from 102 to 87 mmHg (intent-to-treat analysis) and 62% of patients were normalized (diastolic blood pressure below 90 mmHg) at the last evaluable visit. Overall, serum lipids were favourably affected during quinapril treatment; when corrected for changes in body weight, a significant improvement in total, low- and high-density lipoprotein cholesterol, and triglycerides was detected. Quinapril treatment in elderly patients was efficacious and well tolerated, and quinapril appears to be an effective antihypertensive drug devoid of untoward effects on metabolic risk factors for cardiovascular diseas
- …
